Time Commitment: 5 hours over 56 days
Credits Available: 5.0 AMA PRA Category 1 Credit

Multiple myeloma (MM) is a clonal plasma cell disorder arising from the bone marrow and is the second most common hematologic malignancy in the United States (US), with an incidence of approximately 35,000 new cases per year. While progression-free survival (PFS) benefit is often seen with MM therapeutics, overall survival (OS) benefit is rarely seen with novel therapies, and improvements in PFS are still associated with adverse events and long-term disease refractoriness. Over the past few decades, rigorous pre-clinical and clinical research has led to the discovery of novel therapies that have dramatically changed the treatment landscape of MM in the frontline as well as in the relapsed/refractory setting. Despite implementing multimodal approaches to treat MM, the major challenge remains that the vast majority of patients eventually relapse and become refractory to multiple drug classes. Additionally, patients require continuous treatment throughout the disease course, which can negatively affect their quality of life due to potential therapy-related side effects. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with multiple myeloma.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Hematology/Oncology

Christopher Ferreri

Atrium Health Wake Forest Baptist - Levine Cancer Institute
Clinical Assistant Professor

Dr. Ferreri is board certified in internal medicine, hematology, and medical oncology. Conditions he treats include plasma cell disorders, monoclonal gammopathy of undetermined significance, light chain amyloidosis, Waldenstrom macroglobulinemia (a blood cell cancer) and multiple myeloma.

Dr. Ferreri is a clinical assistant professor in the Department of Hematologic Oncology and Blood Disorders at Atrium Health Levine Cancer Institute. His research focuses on clinical and translational research involving multiple myeloma and CAR T-cell therapy. He has authored multiple publications and presented at conferences relating to CAR T-cell therapy for multiple myeloma.

Dr. Ferreri has received an American Society of Hematology (ASH) Abstract Achievement Award and an International Myeloma Society (IMS) Young Investigator Award.

He received his bachelor’s degree in molecular genetics and his medical degree at The Ohio State University. He completed residency at Duke University and a fellowship at The University of Texas MD Anderson Cancer Center, where he was named LBJ Oncology Clinical Fellow of the Year.

Outside of work, he is an avid sports fan who enjoys restaurants and the Blue Ridge Mountains. He loves spending time with his wife, family, friends and dog, a Cavapoo named Benny.